Xencor Inc (FRA:XE9)
€ 23.4 0.4 (1.74%) Market Cap: 1.63 Bil Enterprise Value: 1.19 Bil PE Ratio: 0 PB Ratio: 2.35 GF Score: 59/100

Xencor Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 11:20PM GMT
Release Date Price: €30.06 (+2.07%)
Bassil I. Dahiyat
Xencor, Inc. - Co-Founder, CEO, President & Director

It's a pleasure to be here at the Bank of America conference in Las Vegas. I'm Bassil Dahiyat, CEO of Xencor. We're a monoclonal antibody engineering company.

This is our safe harbor slide. You can, of course, always check our filings with the SEC, the 10-Qs and 10-Ks.

We are a protein engineering company and what we focused on is engineering monoclonal antibodies to make them better therapeutics, essentially engineering their immunological properties and their stability and their structures to make better drugs.

We have built really a large intellectual property base around specifically engineering that bottom half of antibodies, it's shown in blue on that diagram on your right. That's called the Fc domain, and that's a part of the antibody that controls many of these features.

We've built a large toolkit that lets us create different kinds of antibody drugs with different advantages and use that to build both a large internal pipeline as well as a number of partnerships.

Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot